|  |  |
| --- | --- |
|  | **NHS Prescription Services**Bridge House152 Pilgrim StreetNewcastle upon TyneNE1 6SN0845 850 0001 Email:nhsbsa.prescriptionservices@nhsbsa.nhs.ukWebsite:[www.nhsbsa.nhs.uk](http://www.nhsbsa.nhs.uk)  31 Mar 2025 |
|  |

VERSION 3.4.0

Dear dm+d User,

**Addition of 'Ingredients for VTMs' in dm+d (XML) release files and SNOMED CT UK Drug Extension**

The recent work to add the ingredients to Virtual Therapeutic Moieties (VTMs) that needed populating has been completed.

The [dm+d Editorial Policy](https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/dictionary-medicines-and-devices-dmd) has now been updated to reflect the latest policy and will continue to be updated as-and-when any other exclusions are identified

**Please note that VTM Ingredients information will only be available via TRUD and the NHS England Terminology Server from 23 September 2024 and will not be seen in the dm+d browser until further notice is provided.**

Additional information about the change is available on the following [webpage](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures/changes-to-digital-terminologies/addition-of-ingredients-for-vtms-in-dm-d-xml-release-files-and-snomed-ct-uk-drug-extension).

**USER FEEDBACK SOUGHT**

**Misalignment between the terminologies remains for a small subset of identifiers**

* We are unable to map some ingredient identifiers to their respective VTMs.
* Realignment requires reuse of identifiers, restricted by current Editorial Policy
* W**e require feedback from dm+d users** on the impact of reusing identifiers.

Please contact us with any concerns at dmdenquiries@nhsbsa.nhs.uk with subject heading “Impact of reuse of identifiers

If you have any specific queries relating to the dm+d and SNOMED CT UK Drug Extension changes, please contact nhsdigital.ukmeds@nhs.net

**Share your views - Updating the SNOMED CT UK Drug Extension model​ to reflect the SNOMED International model for national drug extensions**

As part of the [UK Medicines Terminology Futures](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures) work, NHS England is seeking views from SNOMED CT UK Drug Extension users regarding updating the SNOMED CT UK Drug Extension model to reflect the SNOMED International model for national drug extensions.

The purpose of NHS England obtaining users views is to ensure they understand the impacts of this work and how much lead in time is required by users to manage the changes, so they can work collaboratively with users to implement these changes.

Supporting information about this work can be found on the [Updating the SNOMED CT UK Drug Extension model](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures/changes-to-digital-terminologies/updating-the-snomed-ct-uk-drug-extension-model) webpage.

NHS England has produced a [survey](https://forms.office.com/Pages/ResponsePage.aspx?id=slTDN7CF9UeyIge0jXdO4-zokzbQpLFJhG318l97n0xUM0FDSTUyNklMMzQ0QURWTzRaVU9PNk5FVy4u) and would really value your insights and feedback by **5pm Tuesday 22 April 2025**

If users have any issues completing the survey or would like to discuss this work further, please contact: nhsdigital.ukmeds@nhs.net

**Survey: dm+d and SNOMED CT UK Drug Extension release cycles**

We are providing an update regarding the [user survey for dm+d and SNOMED CT UK Drug Extension release cycles](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures/changes-to-digital-terminologies/survey-dm-d-and-snomed-ct-uk-drug-extension-release-cycles) which ran from 11 November to 6 December 2024.

The purpose of the survey was to seek viewsfrom users of dm+d and/or SNOMED CT UK Drug Extension data, to understand preferences for release timings of the two terminologies and potential impacts if they were changed.

Firstly, thank you to everyone who submitted a response and for providing your views.

NHS England has analysed the survey responses. A summary of the findings are:

* Based on user preferences, the release timings of both dm+d and SNOMED CT UK Drug Extension will remain at their current frequencies
* There is strong interest from users to access a ‘live data feed’ ([NHS England Terminology Server](https://digital.nhs.uk/services/terminology-server)) to provide greater alignment and ‘real-time’ data between terminologies and release cycles. NHS England will undertake further engagement to understand what information users need to help them make an informed decision
* A small number of users have requested an additional dedicated Drug Tariff dm+d release to the current weekly releases for the end of each month to support their Drug Tariff data processing. NHS England will undertake further work to understand the feasibility of delivering this

Further information will be shared once available.

If you would like to discuss this work further, contact nhsdigital.ukmeds@nhs.net

**Monthly dm+d Supplier Workshop**

NHS England hosts a monthly workshop for IT system suppliers to discuss dm+d content and implementation queries.  It is an opportunity to speak with colleagues from NHS England and the NHSBSA who manage the terminology.

If you are a system supplier who is interested in joining the group, please contact medicinestandards@nhs.net for more information.

**DHSC require these concepts to be made available and visible (similar to licensed medicines) in prescribing and dispensing systems for the time being.**

|  |
| --- |
| **Specials/Imports added at request of DHSC to mitigate shortages in the supply chain** |
| **AMP Name** | **AMP SNOMED Code** | **Import/Special** | **dm+d extract date** |
| Desmopressin 150micrograms/dose nasal spray | 38955011000001100 | Imported  | 14/09/2020 |
| Desmopressin 150micrograms/dose nasal spray | 38996011000001101 | Special Order | 21/09/2020 |
| Capsaicin 0.025% cream | 41539411000001105 | Imported | 27/03/2023 |
| Capsaicin 0.075% cream | 41540711000001105 | Imported | 27/03/2023 |
| Griseofulvin 125mg tablets | 42441511000001104 | Imported (United States) | 27/11/2023 |
| Griseofulvin 500mg tablets | 42441811000001101 | Imported (United States) | 27/11/2023 |
| Hydrogen peroxide 3% solution  | 42510811000001109 | Imported | 18/12/2023 |
| Creon 10000 capsules | 43034611000001101 | Imported | 15/07/2024 |
| Creon 25000 capsules | 43034811000001102 | Imported | 15/07/2024 |
| Pancreaze Delayed-Release capsules | 43035111000001108 | Imported | 15/07/2024 |
| Ipratropium bromide 250micrograms/1ml nebuliser liquid unit dose vials | 43093511000001105 | Imported | 22/07/2024 |
| Ipratropium bromide 500micrograms/2ml nebuliser liquid unit dose vials | 43094411000001109 | Imported | 22/07/2024 |
| Methylphenidate 18mg modified-release tablets | 43210911000001100 | Imported  | 02/09/2024 |
| Methylphenidate 27mg modified-release tablets | 43211511000001100 | Imported | 02/09/2024 |
| Methylphenidate 36mg modified-release tablets | 43211911000001107 | Imported | 02/09/2024 |
| Methylphenidate 54mg modified-release tablets | 43212411000001109 | Imported | 02/09/2024 |
| Pangrol 10,000 capsules | 43788211000001100 | Imported | 23/09/2024 |
| Pangrol 25,000 capsules | 43788511000001102 | Imported | 23/09/2024 |
| Imiquimod 5% cream 250mg sachets | 41526711000001106 | Imported | 02/12/2024 |
| Quetiapine 50mg modified-release tablets | 44616911000001103 | Imported | 17/02/2025 |
| Quetiapine 150mg modified-release tablets | 44617411000001108 | Imported | 17/02/2025 |
| Quetiapine 200mg modified-release tablets | 44617711000001102 | Imported | 17/02/2025 |
| Quetiapine 300mg modified-release tablets | 44618011000001103 | Imported | 17/02/2025 |
| Quetiapine 400mg modified-release tablets | 44618311000001100 | Imported | 17/02/2025 |
| Fluorouracil 5% cream | 44618611000001105 | Imported | 17/02/2025 |
| Imiquimod 3.75% cream 250mg sachets | 44618911000001104 | Imported | 17/02/2025 |
| Sodium fusidate 250mg tablets | 44619211000001103 | Imported | 17/02/2025 |
| Fusidic acid 250mg/5ml oral suspension | 44619511000001100 | Special Order | 17/02/2025 |
| Desmopressin 10micrograms/dose nasal spray | 44920311000001108 | Imported | 17/03/2025 |
| Flucytosine 500mg capsules | 44920711000001107 | Imported | 17/03/2025 |
| Diazepam 2mg/5ml oral suspension | 19674911000001101 | Special Order | 17/03/2025 |
| Megestrol 160mg tablets  | 44940711000001109 | Imported | 31/03/2025 |
| Levofloxacin 250mg tablets | 44942511000001103 | Imported | 07/04/2025 |
| Levofloxacin 500mg tablets | 44942811000001100 | Imported | 07/04/2025 |

**Invalidation****s**

None

**Advance Notice of Invalidations**

The following concepts will be invalidated mid-April. Following correspondence from Torrent Pharma (UK) Ltd, these concepts have had to be invalidated and in-line with dm+d Editorial Policy invalidation criteria, this is labelled with the ‘erroneous’ reason code.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Lenalidomide 2.5mg capsules (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**23344511000001104 | **VMP SNOMED ID**N/A |
| **VMPP**21 (VMPP not to be made invalid) | **VMPP**N/A |
| **VMPP SNOMED ID**23307311000001107 | **VMPP SNOMED ID**N/A  |
| **AMP**Lenalidomide 2.5mg capsules (Torrent Pharma (UK) Ltd) | **AMP**N/A |
| **AMP SNOMED ID**40655111000001104 | **AMP SNOMED IDN/A** |
| **AMPP**21 capsule | **AMPP**N/A |
| **AMPP SNOMED ID**40655211000001105 | **AMPP SNOMED ID**N/A |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Lenalidomide 5mg capsules (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**41765111000001109 | **VMP SNOMED ID**N/A |
| **VMPP**21 (VMPP not to be made invalid) | **VMPP**N/A |
| **VMPP SNOMED ID**11755111000001102 | **VMPP SNOMED ID**N/A  |
| **AMP**Lenalidomide 5mg capsules (Torrent Pharma (UK) Ltd) | **AMP**N/A |
| **AMP SNOMED ID**40656611000001102 | **AMP SNOMED IDN/A** |
| **AMPP**21 capsule | **AMPP**N/A |
| **AMPP SNOMED ID**40656711000001106 | **AMPP SNOMED ID**N/A |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Lenalidomide 7.5mg capsules (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**29903811000001104 | **VMP SNOMED ID**N/A |
| **VMPP**21 (VMPP not to be made invalid) | **VMPP**N/A |
| **VMPP SNOMED ID**29894711000001101 | **VMPP SNOMED ID**N/A  |
| **AMP**Lenalidomide 7.5mg capsules (Torrent Pharma (UK) Ltd) | **AMP**N/A |
| **AMP SNOMED ID**40656811000001103 | **AMP SNOMED IDN/A** |
| **AMPP**21 capsule | **AMPP**N/A |
| **AMPP SNOMED ID**40657011000001107 | **AMPP SNOMED ID**N/A |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Lenalidomide 10mg capsules (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**41765011000001108 | **VMP SNOMED ID**N/A |
| **VMPP**21 (VMPP not to be made invalid) | **VMPP**N/A |
| **VMPP SNOMED ID**11755611000001105 | **VMPP SNOMED ID**N/A  |
| **AMP**Lenalidomide 10mg capsules (Torrent Pharma (UK) Ltd) | **AMP**N/A |
| **AMP SNOMED ID**40654711000001102 | **AMP SNOMED IDN/A** |
| **AMPP**21 capsule | **AMPP**N/A |
| **AMPP SNOMED ID**40654811000001105 | **AMPP SNOMED ID**N/A |

|  |  |
| --- | --- |
| **VMP**Lenalidomide 15mg capsules (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**11762911000001102 | **VMP SNOMED ID**N/A |
| **VMPP**21 (VMPP not to be made invalid) | **VMPP**N/A |
| **VMPP SNOMED ID**11755911000001104 | **VMPP SNOMED ID**N/A  |
| **AMP**Lenalidomide 15mg capsules (Torrent Pharma (UK) Ltd) | **AMP**N/A |
| **AMP SNOMED ID**40654911000001100 | **AMP SNOMED IDN/A** |
| **AMPP**21 capsule | **AMPP**N/A |
| **AMPP SNOMED ID**40655011000001100 | **AMPP SNOMED ID**N/A |

|  |  |
| --- | --- |
| **VMP**Lenalidomide 20mg capsules (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**29903711000001107 | **VMP SNOMED ID**N/A |
| **VMPP**21 (VMPP not to be made invalid) | **VMPP**N/A |
| **VMPP SNOMED ID**29895311000001101 | **VMPP SNOMED ID**N/A  |
| **AMP**Lenalidomide 20mg capsules (Torrent Pharma (UK) Ltd) | **AMP**N/A |
| **AMP SNOMED ID**40655311000001102 | **AMP SNOMED IDN/A** |
| **AMPP**21 capsule | **AMPP**N/A |
| **AMPP SNOMED ID**40655411000001109 | **AMPP SNOMED ID**N/A |

|  |  |
| --- | --- |
| **VMP**Lenalidomide 25mg capsules (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**11763011000001105 | **VMP SNOMED ID**N/A |
| **VMPP**21 (VMPP not to be made invalid) | **VMPP**N/A |
| **VMPP SNOMED ID**11756311000001105 | **VMPP SNOMED ID**N/A  |
| **AMP**Lenalidomide 25mg capsules (Torrent Pharma (UK) Ltd) | **AMP**N/A |
| **AMP SNOMED ID**40656411000001100 | **AMP SNOMED IDN/A** |
| **AMPP**21 capsule | **AMPP**N/A |
| **AMPP SNOMED ID**40656511000001101 | **AMPP SNOMED ID**N/A |

dm+d Authoring Team